# US 2026/0083692 A1 · Methods of treating disease with dichlorphenamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0083692 A1
- Document ID: US20260083692A1
- Status: Published application
- Kind: A1
- Application number: 19/361,331
- Filed: 2025-10-17
- Published: 2026-03-26
- Earliest claimed: 2018-11-27
- Assignees: Strongbridge Dublin Limited
- Applicants: Strongbridge Dublin Limited
- Inventors: Fredric Jay COHEN
- Web page: https://patentgrep.com/patent/US20260083692A1

## CPC

- A61K 31/18: Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/12: for electrolyte homeostasis
- G01N 33/5014: {for testing toxicity}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods for administering dichlorphenamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the subject is also being administered an organic anion transporter-1 (OAT1) substrate to treat an associated disease or disorder. The method comprises administering to the subject a therapeutically effective amount of dichlorphenamide, or a pharmaceutically acceptable salt thereof, and monitoring the subject for signs and symptoms of toxicity and clinical response associated with the OAT1 substrate.

## Claims

### Claim at position 1

1-12. (canceled)

### Claim 13

A method of administering dichlorphenamide to treat primary hyperkalemic periodic paralysis or primary hypokalemic periodic paralysis in a human patient in need thereof, wherein the patient is also being administered oseltamivir for the treatment of a disease or disorder, the method comprising:
discontinuing administration of the oseltamivir to said patient, and
administering dichlorphenamide in a tablet form to said patient at an initial dose of 50 mg once or twice daily, thereby avoiding concomitant administration of oseltamivir and dichlorphenamide to said patient.
